Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPsychiatry/Behavioral HealthAetna Eating Disorders Coverage & Policy Update | …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0511

    Eating Disorders

    Customize your policy alerts

    Sign up for Aetna Policy 0511 alerts

    Get alerted when Policy 0511 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's medical necessity, experimental/investigational determinations, covered assessments and treatments, and related coding for management of anorexia nervosa, bulimia nervosa and binge-eating disorder for insured members.

    Policy Summary
    PayerAetna
    PolicyEating Disorders
    Policy CodePolicy 0511
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewAug 1, 2023
    Next Review DateN/A
    Key ActionDocument medical evaluation including history, physical, laboratory tests (CBC, electrolytes, LFTs), ECG and psychiatric assessment when submitting for coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~40+References listed
    84% / 80%SCOFF accuracy (adult)
    15-20%AN lifetime mortality (female)
    4 RCTsLisdexamfetamine BED trials
    10 studiesEnteral nutrition studies (AN)

    Coverage Criteria

    inv-01: Assessment (Medically necessary)

    Medically necessary when ALL of the following assessment components are documented:

    Assessment components: Complete medical evaluation including detailed history and physical examination; psychiatric or psychological consultation and testing; blood count and serum chemistry (e.g., CBC, electrolytes, BUN/creatinine); liver function tests; urinalysis; electrocardiography; bone density measurement for evaluation of anorexic members.

    Documentation should include results and clinical interpretation; bone density testing targeted to anorexic patients as noted.

    inv-02: Treatment (Medically necessary)

    Covered treatments when clinically indicated and documented:

    Core treatments: Nutritional counseling with a graduated eating plan tied to specific weight goals; psychotherapy (eg, cognitive behavioral therapy, family psychotherapy, interpersonal psychotherapy, psychodynamic psychotherapy); pharmacotherapy as appropriate to diagnosis (eg, SSRIs and antipsychotics in anorexia; fluoxetine, TCAs, trazodone, topiramate for bulimia; lisdexamfetamine for binge-eating disorder)

    Pharmacotherapy subject to formulary restrictions and plan benefit exclusions for weight‑altering medications; enteral nutrition only as a last resort for anorexia.

    inv-03: Experimental / Investigational (Not established)

    The following services are considered experimental and investigational (not established) due to insufficient evidence:

    Assessment - Experimental/Investigational: Routine screening of asymptomatic adolescents and adults for eating disorders; blood-based serotonergic biomarkers; brain imaging (MRI, PET, SPECT) for diagnosis or treatment tailoring; genotyping for COMT, ESR1, 5-HTTLPR, MC4R and other polymorphisms; EEG for management; gustatory/olfactory testing; Individual Optimal Nutrition (ION) profiling; measurement of peripheral biomarkers (BDNF, adiponectin, hypothalamic neuropeptides, polyunsaturated fatty acids); serum zinc measurement.

    Listed as experimental/investigational for diagnosis and treatment.

    Treatment - Experimental/Investigational: Acamprosate; acupuncture; cannabinoids; cholinesterase inhibitors; chromium; deep brain stimulation for treatment‑refractory anorexia; DHEA; electroconvulsive therapy; estrogen/HRT for bone in AN; e‑therapy (internet/mobile apps); biofeedback/neurofeedback; food‑specific inhibition training; ghrelin agonists; GLP‑1 receptor agonists; intranasal naloxone; liraglutide; melatonergic medications for night eating; music therapy; neural therapy (superficial injection); oral contraceptives for bone loss prevention; oxytocin; phentermine/topiramate ER (Qsymia); relaxation therapy; repetitive TMS; Mandometer residential treatment; transcranial direct current stimulation (tDCS).

    Listed as experimental/investigational for treatment.

    inv-04: Coverage-considerations based on evidence

    Evidence-based considerations and implied coverage positions:

    Pharmacotherapy for bulimia: Fluoxetine is the only medication with regulatory approval for bulimia nervosa; fluoxetine and evidence‑based psychotherapy should be considered first‑line.

    From evidence reviews and guideline summaries.

    Pharmacotherapy for anorexia: No medications have proven efficacy for acute anorexia nervosa; atypical antipsychotics (eg, olanzapine) have mixed/preliminary data and pharmacotherapy should not replace weight restoration and behavioral treatment.

    AHRQ and subsequent reviews.

    Pharmacotherapy for BED: Some agents (eg, lisdexamfetamine, bupropion, chromium, intranasal naloxone in early RCTs) show preliminary benefit for reducing binge episodes; evidence quality varies and further trials are needed.

    Multiple RCTs and systematic reviews summarized.

    Coverage of pharmacologic treatment is subject to plan and formulary rules. The policy lists pharmacotherapy as a medically necessary treatment option for anorexia, bulimia and binge‑eating disorder but notes that coverage of particular drugs may be subject to formulary restrictions. In addition, the policy explicitly warns that coverage of lisdexamfetamine for binge‑eating disorder may be excluded under plans that exclude medications to decrease or increase weight; reviewers and billing staff should confirm member benefit documents before authorizing or submitting claims.

    The policy identifies the Mandometer residential program and the ION™ (Individual Optimal Nutrition) analysis/profile as interventions with limited or unestablished clinical value. The Mandometer program’s published evidence is largely from a single Swedish group and non‑comparative series; Aetna notes that effectiveness has not been established and that a randomized trial versus standard care is needed. Similarly, the ION profile is described as a broad panel of biochemical and nutrient measures for which there is a lack of evidence supporting clinical value in diagnosing or evaluating eating disorders. These modalities may therefore be treated as investigational or excluded depending on plan rules.

    The policy highlights a safety concern for application of excitatory non‑invasive brain stimulation (notably rTMS) in anorexia nervosa: narrative reviews report a trend toward iatrogenic weight loss with excitatory NIBS in AN and conclude that excitatory stimulation may be contraindicated on theoretical and empirical grounds. This caution should inform clinical decision‑making and payer review of requests for rTMS in members with anorexia.

    The document summarizes background research across many diagnostic and treatment approaches without making standalone coverage determinations for each. For several novel or emerging interventions (for example, residential programs, device‑based neuromodulation, and e‑therapies), the available studies are small, single‑center, or uncontrolled and thus insufficient to establish long‑term effectiveness. The policy therefore compiles the evidence base and flags modalities as experimental/investigational where peer‑reviewed data do not meet standards for established medical benefit.

    The USPSTF‑commissioned systematic review cited in the policy limited its analysis to adolescents and adults without underweight or overt physical signs of an eating disorder; accordingly, evidence that is limited to under‑weight populations or to patients with physical signs (e.g., rapid weight loss, pubertal delay, bradycardia, oligomenorrhea or amenorrhea) was excluded from that review. The policy notes the USPSTF conclusion that current evidence is insufficient to determine the balance of benefits and harms of screening in adolescents and adults without signs or symptoms.

    The policy lists numerous diagnostic tests and therapeutic approaches that are considered experimental and investigational because of insufficient peer‑reviewed evidence. Examples include: brain imaging (MRI, PET, SPECT) for diagnosis/treatment planning; a range of genetic polymorphism tests (COMT, ESR1, 5‑HTTLPR, MC4R); blood‑based serotonergic biomarkers; EEG for management; gut microbiota evaluation; the ION nutritional profiling; measurement of multiple peripheral biomarkers (BDNF, adiponectin, hypothalamic neuropeptides, polyunsaturated fatty acids); and measurements of serum zinc. On the treatment side, listed investigational therapies include acupuncture, ghrelin agonists, GLP‑1 receptor agonists, intranasal naloxone, liraglutide, neural therapy, biofeedback/neurofeedback, music therapy, Mandometer treatment, repetitive TMS, deep brain stimulation for refractory anorexia, and many others. These items are identified in the policy’s Experimental and Investigational section and should be handled as not medically necessary absent compelling peer‑reviewed evidence and applicable plan language.

    A small randomized, double‑blind, sham‑controlled trial of rTMS in bulimia nervosa (Walpoth et al., n=14) found no additional benefit of active stimulation over sham on bingeing and purging or commonly used mood and obsessive‑compulsive scales. The policy cites these negative randomized data when listing repetitive transcranial magnetic stimulation for BN among investigational or not‑medically‑necessary interventions.

    Within the excerpted material there are numerous statements identifying investigational procedures and summarizing evidence, but the text does not always include explicit formal determinations phrased as 'not medically necessary' for every intervention. Instead, the policy groups many interventions into an Experimental and Investigational list and states that items in that list are considered investigational because evidence is insufficient; reviewers should reference the Experimental and Investigational section for specific determinations rather than expect a separate 'not medically necessary' statement for each item in this excerpt.

    Coding

    Covered CPT/HCPCS codes if selection criteria are metmixedCovered
    76977Ultrasound bone density measurement and interpretation, peripheral site(s), any method.
    77078Computerized tomography, bone mineral density study, 1 or more sites.
    77080Dual energy x-ray absorptiometry (DXA), bone density study, 1 or more sites.
    77081Dual energy x-ray absorptiometry (DXA), additional code (listed in range 77080 - 77081).
    80047Basic metabolic panel (Calcium, ionized).
    80048Basic metabolic panel (Calcium, total).
    80050General health panel.
    80053Comprehensive metabolic panel.
    80076Hepatic function panel.
    81000Urinalysis.
    1–10 of 64
    1/7
    Codes listed as not covered / related not-covered groupsmixedNot Covered
    70450Computed tomography, head or brain (listed in range 70450 - 70470).
    70496Computed tomographic angiography, head, with contrast material(s).
    70551Magnetic resonance imaging, brain (listed in range 70551 - 70553).
    70554Functional MRI, brain (listed in range 70554 - 70555).
    78600Brain imaging (nuclear medicine) (listed in range 78600 - 78610).
    81403Molecular pathology procedure level 4.
    84630Zinc (measurement).
    96900Actinotherapy (ultraviolet light).
    97812Acupuncture subsequent sessions (listed in range 97810 - 97814).
    A4633Replacement bulb/lamp for ultraviolet light therapy system.
    1–10 of 13
    1/2
    ICD-10 codesICD-10
    F50.00Anorexia nervosa.
    F50.01Anorexia nervosa, other.
    F50.02Anorexia nervosa, unspecified.
    F50.2Bulimia nervosa.
    F50.81Binge eating disorder.
    F50.82Avoidant/restrictive food intake disorder.
    R63.0Anorexia.
    Z13.21Encounter for screening for nutritional disorder [eating disorders] (listed as not covered).
    No explicit billing codes in this excerptmixed
    No codes listed
    Anorexia weight threshold
    Percent of expected body weight< 85% of expected body weight
    BMI threshold noteConsider diagnosis with BMI ≤ 17.5 kg/m2
    Clinical features (related)Disturbance in body image and, in post‑menarcheal females, amenorrhea
    Bulimia frequency criterion
    Minimum frequencyBinge eating with inappropriate compensatory behaviors ≥ 2 times per week
    Minimum durationFor at least ≥ 3 months (average)

    Provider Actions & Administrative Notes

    Billing Rule

    Advanced procedures / implant coding noted

    Advanced procedures and implant-related codes (e.g., deep brain stimulation CPT codes) are listed as not covered for indications in this CPB — verify coding and medical necessity prior to submission to avoid denials.

    • Not-covered CPT examples: 61863, +61864, 61867, +61868, 61880
    Prior Authorization

    Prior authorization for experimental/long-term programs

    Prior authorization may be required for experimental, novel, or long-term residential/specialty programs (for example, unproven modalities like Mandometer residential programs). Submit clinical rationale, prior treatment history, objective measures of severity, and expected length of stay when requesting authorization.

    Background

    Eating disorders include anorexia nervosa and bulimia nervosa and typically present in adolescence or young adulthood with a predominance in females. The policy notes estimated lifetime prevalence in adult women (e.g., AN 1.42%, BN 0.46%, BED 1.25%) and lower prevalence in men, and highlights the potential for severe medical complications. Most patients can be managed in outpatient settings; hospitalization is reserved for severe medical instability (for example, extreme low body weight, electrolyte disturbances, cardiac arrhythmias, or suicidality). Weight restoration and multidisciplinary care (medical monitoring, nutritional counseling and psychotherapy) are central to management.

    Definitions

    Anorexia nervosa definition
    Core weight criterionRefusal/ failure to maintain minimally normal weight — e.g., <85% of expected body weight
    BMI considerationConsider diagnosis with BMI ≤ 17.5 kg/m2 (young woman with amenorrhea)
    Associated clinical featuresDisturbance of body image and, in post‑menarcheal females, amenorrhea (absence of 3 consecutive cycles)
    Bulimia nervosa definition
    Binge and compensatory behavior definitionRecurrent binge eating with inappropriate compensatory behaviors (purging, restriction, excessive exercise)
    Frequency and timeframeOccurs on average at least twice weekly for ≥3 months

    Level of Care Criteria

    inv-68: Inpatient/Medical refeeding (enteral nutrition) — evidence summary

    Evidence summary for enteral nutrition in anorexia nervosa:

    NG enteral nutrition evidence: Nasogastric (NG) enteral nutrition increases caloric intake and commonly produced average weight gain >1 kg/week in multiple in‑hospital studies; prophylactic phosphate supplementation reduced refeeding hypophosphatemia incidence to <1 % in reported studies.

    Used as medical refeeding in inpatient settings and considered when oral refeeding insufficient or life‑threatening condition present.

    Treatment Modalities

    inv-70: Psychotherapy, Nutritional Counseling, Pharmacotherapy

    Psychotherapy: Cognitive behavioral therapy, family psychotherapy, interpersonal psychotherapy, and psychodynamic psychotherapy are core, medically necessary modalities.

    Primary behavioral treatments; indicated across eating disorder presentations as clinically appropriate.

    Nutritional counseling with a graduated eating plan tied to specific weight goals and monitoring is essential; enteral nutrition reserved as last resort for anorexia.

    Nutrition emphasized as central intervention.

    Pharmacotherapy roles defined by disorder: limited role in anorexia (SSRIs, antipsychotics have mixed evidence); fluoxetine for bulimia; lisdexamfetamine and other agents for BED per trial evidence and approval status.

    Subject to formulary restrictions and benefit exclusions for weight‑altering medications.

    inv-71: rTMS

    Visit Limits

    Visit limits — informational
    Visit limits statementNo explicit visit limits specified in this excerpt; CPT psychotherapy and related service codes are listed as covered if selection criteria are met
    Covered service codesExamples include psychotherapy CPT codes 90832–90838, diagnostic codes 90791–90792, and related assessment/testing codes
    Operational notePlan‑specific coverage and prior authorization requirements are not detailed in these chunks
    Visit limits — provider informational note
    Visit limits statementNo explicit visit limits stated in this excerpt
    Provider noteResidential programs (e.g., Mandometer) and specialty services discussed but payer‑level visit caps are not provided

    References & Revision History

    References cited in the policy include guideline and systematic review sources and key randomized trials across pharmacologic, psychotherapy, neuromodulation and nutritional interventions. Representative citations include practice parameters and reviews (AACAP/APA sources), randomized trials and RCTs (e.g., lisdexamfetamine trials for BED), systematic reviews of neurostimulation and enteral nutrition, and topical studies on biomarkers and genetics. See the policy’s reference list for full citations and to guide further literature review.

    08/01/2023last_reviewLatest

    Clinical policy bulletin last reviewed.

    06/11/2001effective_date

    Policy effective date established.

    Policy Summary
    PayerAetna
    PolicyEating Disorders
    Policy CodePolicy 0511
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewAug 1, 2023
    Next Review DateN/A
    Key ActionDocument medical evaluation including history, physical, laboratory tests (CBC, electrolytes, LFTs), ECG and psychiatric assessment when submitting for coverage.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions & Administrative NotesBackgroundDefinitionsLevel of Care CriteriaTreatment ModalitiesVisit LimitsReferences & Revision History
    Novel/device-based treatments:
    Interventions such as Mandometer residential programs, ION nutritional profiling, ghrelin infusion, rTMS for BN, and other device‑based or residential programs lack sufficient high‑quality evidence or replication to be considered established therapies.

    Small/single‑center RCTs or single‑group data; further controlled trials required.

    Bone health in anorexia: There is no consistent evidence that bisphosphonates or routine hormone replacement reliably improve bone mineral density outcomes in anorexia; prioritize early detection and weight restoration before medicinal interventions.

    Systematic reviews and guideline recommendations.

    Typical compensatory behaviorsPurging, restriction, or excessive exercise following binge episodes
    BMI inclusion for liraglutide trial
    BMI inclusion for liraglutide trial>= 27 kg/m2
    Trial duration and dose (pilot)17‑week trial of liraglutide 3.0 mg/day (pilot RCT)
    Primary outcome contextOBEs/week (no significant difference); greater percent weight loss with liraglutide
  1. Document prior outpatient treatment attempts and clinical need for higher level of care
  2. Include program description and planned therapeutic components
  3. Provide expected treatment duration and measurable goals
  4. Prior Authorization

    Lisdexamfetamine (Vyvanse) for BED

    Lisdexamfetamine (Vyvanse) is an FDA‑approved pharmacotherapy for binge‑eating disorder (BED). Coverage may be subject to formulary restrictions or plan exclusions for weight‑altering medications; prior authorization may apply per benefit plan.

    • Check member's drug formulary and any PA or quantity limits
    • If PA required, provide BED diagnosis, prior therapies tried, and treatment goal
    Note

    Prior authorization not specified in excerpt

    In the provided excerpts, no specific prior authorization requirements are explicitly stated for many services (e.g., enteral nutrition supplies, NG feeding). Treating providers should check the member's benefit plan and medical policy for any PA rules before providing services.

    • Verify benefit plan prior authorization rules for enteral nutrition and related supplies
    • Coding lists do not equate to PA approval — submit clinical documentation as needed
    Note

    Prior authorization not specified in provided text

    Some coding entries and background sections note that prior authorization is not specified in the provided text (e.g., enteral nutrition HCPCS groups). This is informational; operational PA rules may be maintained separately.

    • Check administrative PA lists or pharmacy benefit for medication-specific requirements
    • Do not assume no PA — confirm with payer portal or policy documents
    Note

    Prior authorization not specified in this section

    Within this section, no explicit prior authorization or utilization management rules are stated for several interventions (e.g., DBS, NG feeding, residential programs). Operational PA requirements should be confirmed with the payer.

    • Confirm PA requirements for investigational/high-cost procedures (e.g., DBS) before referral
    • When in doubt, submit pre-service review to avoid retrospective denials
    Denial Risk

    Screening code not covered

    Screening for eating disorders (ICD-10 Z13.21) is designated as not covered in this CPB because screening clinical value has not been established in the literature presented.

    • Do not bill Z13.21 for covered diagnostic services under this CPB; use diagnostic codes when clinical disorder is identified
    Denial Risk

    Investigational modalities risk denial

    Investigational modalities (for example, Mandometer programs, certain residential treatments, DBS for AN) carry a risk of denial because clinical value and long-term effectiveness have not been established.

    • Document rationale and evidence when requesting authorization for novel modalities
    • Be prepared for denials when therapies are labeled investigational in policy
    Denial Risk

    Lack of controlled trials showing long‑term effectiveness

    There is a documented lack of controlled trials demonstrating long‑term effectiveness for some higher‑level care settings (notably residential treatment) and for several interventions, which may limit coverage justification for prolonged stays or novel programs.

    • Provide objective outcome data and justification for continued length of stay when requesting ongoing coverage
    • Consider step‑down to evidence‑based outpatient or PHP where appropriate
    Note

    Not applicable in this excerpt — no explicit operational rules

    Not applicable in this excerpt: no explicit step therapy or formal utilization management rules are detailed. Use the policy content as clinical guidance and consult administrative PA/UM documents for operational rules.

    • Operational rules (PA, step therapy) may be maintained separately from this CPB
    • Contact payer UM team for program‑specific authorization criteria
    Note

    No explicit authorization or prior‑approval stated

    The excerpt does not state explicit authorization or prior‑approval processes for many services; providers must verify PA requirements through the payer's administrative channels.

    • Confirm PA for high‑cost medications, implants, and residential services before initiating treatment
    • Include supporting clinical documentation with any PA request
    Documentation Required

    Required assessment documentation

    Required assessment documentation for medical necessity determinations should include medical history and physical exam details, psychiatric/psychological evaluation, relevant labs (CBC, electrolytes, BUN/creatinine, LFTs), EKG results, and bone density testing when indicated.

    • Include baseline weight/percent expected body weight and recent weight trend
    • Attach relevant lab results and EKG when requesting higher level of care or enteral nutrition
    Documentation Required

    Bone health therapy documentation

    When documenting bone‑health therapies (e.g., bisphosphonates, hormone replacement), include rationale, prior efforts at weight restoration, bone mineral density results, fracture history, and discussion of limited evidence and risks.

    • Document failure of or contraindication to weight restoration when proposing bone‑targeted therapy
    • Note informed consent discussing uncertain benefit and potential risks
    Documentation Required

    When naso‑gastric feeding is used for AN

    When naso‑gastric (NG) feeding is used for anorexia nervosa, document the indication (e.g., life‑threatening malnutrition or failure of oral refeeding), short‑term weight gain goals, monitoring plan (electrolytes, refeeding protocol), and adherence issues.

    • Provide daily caloric targets and expected rate of weight gain
    • Document monitoring for refeeding syndrome and prophylactic measures (eg, phosphate supplementation)
    Note

    No explicit documentation or medical necessity template provided

    No explicit documentation templates or medical necessity checklists are provided in the excerpts; use the assessment and treatment elements noted in the policy as the basis for documentation submitted for authorizations.

    • Supply clinical notes, lab results, psychiatry/psychology evaluations, and prior treatment chronology when requesting authorization
    Step Therapy

    Pharmacotherapy sequencing note

    Pharmacotherapy sequencing: prioritize weight restoration and evidence‑based psychosocial therapies for anorexia nervosa before initiating pharmacologic treatments; for bulimia, use evidence‑based agents (e.g., fluoxetine) as first‑line when indicated.

    • For AN: emphasize nutritional rehabilitation and psychotherapy before meds
    • For BN: consider fluoxetine before other agents unless contraindicated
    Step Therapy

    Step from evidence‑based therapy to experimental medications

    When considering experimental or off‑label medications, step from established evidence‑based therapies to novel agents only after documented failure or intolerance of first‑line treatments; include risk/benefit discussion and safety monitoring plan.

    • Document prior trials of psychotherapy and approved/standard pharmacotherapies
    • Include monitoring plan for adverse effects and objective outcome measures
    Step Therapy

    Medication selection considerations

    Medication selection considerations: fluoxetine is the only FDA‑approved medication for bulimia nervosa; other agents (eg, topiramate, bupropion, lisdexamfetamine) have mixed evidence or specific safety concerns that should be documented when used.

    • Avoid bupropion in bulimia due to seizure risk
    • When using topiramate or stimulants, document informed consent and monitor for adverse events
    Note

    No formal step‑therapy rules are specified

    No formal step‑therapy rules are specified in the provided excerpts; the document summarizes trial evidence and clinical guidance but does not prescribe utilization management sequencing.

    • Operational step therapy, if any, should be confirmed via administrative PA criteria
    Note

    No step‑therapy rules are described in the text

    Several study summaries describe pharmacotherapy trials and suggested sequences, but no operational step‑therapy rules are described in the text — these are clinical references, not UM directives.

    • Use clinical trial evidence to support medical necessity but verify payer's step therapy lists separately
    Typical weight status
    Individuals are generally in the normal weight range despite recurrent weight changes
    Anorexia nervosa (AN) — evidence context
    Medication roleNo medications have proven efficacy for acute anorexia nervosa; pharmacotherapy has a limited role
    Behavioral therapiesBehavioral therapies may help prevent relapse and offer limited benefits
    Clinical priorityWeight restoration and medical stabilization are essential components of treatment
    Bulimia nervosa (BN) — evidence context
    Responsive treatmentsBulimia nervosa responds to certain medications (fluoxetine) and behavioral therapies
    FDA‑approved medicationFluoxetine is the only medication approved for bulimia nervosa
    Combination therapy guidanceEvidence provides limited guidance on combining medications with behavioral treatments
    Binge‑eating disorder (BED) — pharmacologic agents and evidence
    Pharmacologic agents with RCT dataLisdexamfetamine, bupropion, chromium (pilot data) show preliminary efficacy for BED
    Evidence variabilityQuality and outcomes vary across agents (binge frequency, weight, metabolic markers) and trials are often small
    Harms and monitoringPharmacotherapies can reduce symptoms but are associated with adverse effects and require clinician judgment
    Night eating syndrome (NES) — definition
    Core definitionNight eating syndrome (NES) is a delayed pattern of food intake with recurrent nocturnal eating and/or excessive consumption after the evening meal
    Clinical associationsAssociated with obesity, sleep disturbances, and psychiatric comorbidity
    Assessment tools and treatmentsUse Night Eating Questionnaire; antidepressants and psychological therapies may be used; melatonergic meds and light therapy hold promise
    BED — lisdexamfetamine approval and indication
    Regulatory approvalLisdexamfetamine is FDA‑approved for adult moderate‑to‑severe BED (first FDA‑approved medication for BED, Jan 30, 2015)
    Supporting trialsEfficacy shown in 2 clinical studies (724 adults) with decreased binge days and obsessive‑compulsive binge behaviors
    Clinical use noteRCT evidence supports benefit; prior authorization or benefit exclusion may apply depending on plan formularies
    COMT Val158Met polymorphism — genetics note
    Genetic polymorphism examinedCOMT Val158Met variant evaluated for association with eating disorders
    Meta‑analysis resultMeta‑analysis pooling 11 studies (7,225 subjects) found no significant association with AN or BN
    InterpretationCurrent evidence does not support COMT Val158Met as a diagnostic marker for EDs
    NG enteral nutrition — definition and usage
    Definition and purposeNG enteral nutrition = nasogastric tube feeding used for refeeding and weight restoration in anorexia nervosa
    Evidence on effectivenessMultiple studies reported average weight gain >1 kg/week and increased caloric intake versus oral‑only feeding
    Safety considerationsProphylactic phosphate supplementation in several studies reduced refeeding hypophosphatemia to <1%
    SCOFF — screening tool and performance
    Tool descriptionSCOFF is a brief screening questionnaire for eating disorders (cut‑point ≥2)
    Performance metrics (adults)Pooled sensitivity 84% (95% CI:74–90%); pooled specificity 80% (95% CI:65–89%)
    Context of useAdequate accuracy for detecting eating disorders among adults; no trials evaluated benefits/harms of screening
    YBOCS‑BE — outcome measure
    Measure descriptionYBOCS‑BE = Yale‑Brown Obsessive Compulsive Scale modified for binge eating
    Use in trialsUsed as an outcome measure in BED trials; lisdexamfetamine and topiramate trials reported changes on YBOCS‑BE
    InterpretationPooled MDs indicate pharmacotherapies reduced YBOCS‑BE scores versus placebo in referred BED populations
    Eating disorders — examples
    Examples listedEating disorders include anorexia nervosa (AN), bulimia nervosa (BN), and binge‑eating disorder (BED)
    Definition summaryPsychiatric conditions defined by disturbances in eating or eating‑related behaviors impairing physical or psychosocial functioning
    Prevalence notesLifetime prevalence estimates vary by disorder and sex (see source for detailed rates)
    SCOFF questionnaire — screening accuracy
    Duplicate entry noteSCOFF questionnaire (cut‑point ≥2) — pooled sensitivity 84% and specificity 80% in adults
    Evidence sourceMeta‑analysis of test accuracy studies included in USPSTF‑related review (10 studies, n=3,684 adults)
    Screening trial gapNo included studies directly assessed benefits/harms of screening programs in asymptomatic populations
    rTMS evidence and status: A small sham‑controlled RCT in bulimia (Walpoth et al.) found no benefit over placebo; neurostimulation approaches show preliminary promise but lack large, well‑conducted RCTs and are considered investigational for routine use.

    Excitatory NIBS may be contraindicated in anorexia due to a trend toward iatrogenic weight loss in some reports.

    inv-72: Residential behavioral program (Mandometer)

    Mandometer residential program status: Mandometer is a residential program (~12 months) combining meal biofeedback, heat therapy, activity restriction and social reconstruction; effectiveness has not been established in RCTs versus standard care and remains investigational.

    Evidence primarily from single‑group reports and limited trials; not validated as standard care.

    inv-73: Pharmacologic (BED)

    Pharmacologic options for BED: Lisdexamfetamine has RCT evidence and FDA approval for adult BED; other agents including bupropion, chromium, intranasal naloxone, and topiramate have RCT or pilot data showing variable efficacy and safety; selection requires clinician judgment and monitoring.

    Lisdexamfetamine trials demonstrated reductions in binge days; topiramate reduced binge frequency but had higher withdrawal for adverse effects.

    inv-74: Non-invasive and invasive brain stimulation

    Neurostimulation evidence summary: Non‑invasive and invasive brain stimulation (rTMS, tDCS, DBS) show preliminary promise for ED symptoms and craving modulation but evidence is limited, heterogeneous, and lacking large RCTs; parameters and targets require further study.

    DBS has small observational data in treatment‑refractory AN; rTMS/tDCS findings mixed and further trials needed.

    inv-75: Bright light therapy

    Bright light therapy status: Bright light therapy may acutely improve disordered eating behavior and mood in disorders with circadian features (eg, night eating); timing and durability of effect remain uncertain and further research is needed.

    Systematic review identified small studies with short‑term benefit.

    inv-76: Behavioral inhibition training

    Behavioral inhibition training status: Food‑specific inhibition training improved inhibitory control in a small RCT for BED and was feasible; clinical efficacy requires larger confirmatory trials.

    Pilot proof‑of‑concept data support further study.

    inv-77: Pharmacologic treatments

    Pharmacologic treatments summary: Fluoxetine is the only FDA‑approved medication for bulimia; antipsychotics have mixed data in anorexia; pharmacotherapy is adjunctive to psychotherapy and nutrition, not a substitute for weight restoration in AN.

    Guideline and evidence review consensus.

    inv-78: Ghrelin agonists (relamorelin)

    Ghrelin agonists evidence: Relamorelin decreased gastric emptying time and showed a trend toward weight gain after 4 weeks in a small RCT (n=22); further study needed to establish safety and efficacy.

    Preliminary randomized data; not established therapy.

    inv-79: GLP-1 receptor agonists

    GLP-1 receptor agonists status: GLP‑1 receptor agonists are hypothesized to reduce binge eating with biologic rationale and preliminary data; randomized placebo‑controlled trials are proposed but definitive efficacy data are lacking in this excerpt.

    Research and pilot data support further trials.

    inv-80: Phentermine/topiramate ER (Qsymia)

    Phentermine/topiramate ER (Qsymia) evidence: Small randomized and cross‑over trials reported PHEN/TPM‑ER reduced binge eating days and increased abstinence versus placebo in predominantly BED patients; BN sample sizes were very small making conclusions for BN uncertain.

    Preliminary RCT evidence; further study required for routine use in EDs.

    inv-81: Enteral nutrition (nasogastric tube) for AN

    Enteral nutrition (NG) for AN: Nasogastric enteral nutrition increased caloric intake and commonly achieved >1 kg/week weight gain in multiple studies; prophylactic phosphate supplementation reduced refeeding hypophosphatemia incidence to <1% in studies reporting it.

    Used in hospital settings for medical refeeding when oral intake insufficient or life‑threatening condition exists.

    inv-82: Neural therapy (superficial injection)

    Neural therapy status: Neural therapy (superficial local anesthetic injection) has anecdotal case‑report evidence (n=2) suggesting rapid response in bulimia but lacks controlled replication and remains investigational.

    Evidence limited to case reports; controlled studies needed.

    inv-83: Oxytocin (intranasal)

    Oxytocin status: Intranasal oxytocin modulates eating behavior and social/cognitive domains in preliminary studies; therapeutic evidence in AN, BN, and BED is limited and investigational.

    Pilot and early‑phase data only.

    inv-84: Enteral Nutrition (NG)

    Enteral Nutrition (NG) summary: NG feeding in AN resulted in increased caloric intake and weight gain versus oral‑only strategies in several studies; evidence supports efficacy in inpatient refeeding but long‑term outcomes require further study.

    Enteral nutrition considered when clinically indicated; closely monitored in hospital settings.

    inv-85: Pharmacotherapy (lisdexamfetamine, topiramate)

    Pharmacotherapy trials (lisdexamfetamine, topiramate): Lisdexamfetamine demonstrated reductions in binge frequency in multiple RCTs and is FDA‑approved for adult BED; topiramate reduced binge episodes and weight in meta‑analysis but had higher withdrawal rates for adverse events—both require monitoring for harms.

    Evidence includes multiple RCTs and meta‑analyses summarized.

    inv-86: Neurofeedback / EEG / Biofeedback

    Neurofeedback/EEG/Biofeedback: Preliminary and heterogeneous studies of neurofeedback, EEG‑guided interventions and biofeedback indicate possible effects on dysfunctional eating behaviors and brain activity in BED/obesity but evidence is limited and not definitive.

    Systematic reviews report small number of heterogeneous studies; further research needed.

    inv-87: Gut microbiota evaluation / interventions

    Gut microbiota interventions: Studies report intestinal dysbiosis in anorexia with lower microbial diversity; fecal microbiota transplantation and other microbiota‑directed interventions remain investigational with inconsistent evidence.

    Research findings are preliminary and methods heterogeneous.

    inv-88: Pharmacologic, neuromodulation, psychosocial (music therapy)

    Multi‑modality experimental approaches: Various pilot or early‑phase interventions (pharmacologic agents not yet established, neuromodulation techniques, and psychosocial approaches such as music therapy) have shown limited or preliminary benefits in small heterogeneous studies and should be considered investigational until larger confirmatory trials are available.

    Examples include liraglutide pilot trials, DBS for refractory AN (small observational studies), and music‑based interventions with limited generalizability.

    inv-89: Various modalities (pharmacotherapy, psychotherapy, neuromodulation, nutritional support)

    Various modalities summary: The evidence base includes randomized trials and systematic reviews of pharmacotherapies (eg, lisdexamfetamine, topiramate), psychotherapies, electrical and magnetic neuromodulation (rTMS, tDCS, DBS), and nutritional/enteral feeding interventions; many promising modalities remain preliminary and require larger, well‑conducted trials to establish clinical effectiveness and safety.

    Refer to cited references for detailed trial data and systematic reviews.

    ImplicationCoverage of duration or intensity of services may require medical‑necessity review on a case‑by‑case basis
    05/23/2024next_review

    Next scheduled policy review date.